treatment-changing advancements in cll: btk, bcl-2, cd20 & car t-cells
Published 6 years ago • 333 plays • Length 9:35Download video MP4
Download video MP3
Similar videos
-
0:53
k 2022 | rosa silveri's interview
-
1:11
dr. rotow on brigatinib safety profile in alk nsclc
-
1:37
the lindström lab is hiring
-
2:31
cri research opens new doors to better targeting of lung cancer
-
0:52
dr. rotow on remaining questions with brigatinib in alk nsclc
-
3:04
durst tau rsc e
-
2:22
rt3 interviews: ken kelly
-
22:09
ceo chats with rocket lab video
-
2:21
mediapoint customer story: tau 330 rsc e
-
12:49
production insights splitfin customer interview @glas lang
-
29:58
us business summit 2022: peter beck, founder and ceo rocket lab
-
0:30
qilong ying stem cell #sciencepitch challenge
-
5:21
ceritinib alternative dosing for alk nsclc
-
1:21
alta-1l: brigatinib vs crizotinib
-
23:47
the qubit guy's podcast with bob sorensen, senior vp of research at hyperion research
-
0:56
crizotinib for first line treatment of alk or ros1 rearrangements
-
18:34
2018 innovation conference - cast connex high integrity blocks "improving steel connections"
-
1:34
second-line treatments in alk-rearranged nsclc
-
13:57
sales representative interview questions & answers! (how to pass a sales rep job interview!)
-
2:11
ipsc identification kit - stem cell core facilities user testimonials
-
6:12
experience with ceritinib for alk nsclc
-
4:22
carcik trial updates: using sb-engineered car-t cells in patients with b-all